Navigation Links
Treating Knee Ligament Injuries
Date:3/2/2009

Identifying level of injury is key to treating MCLs nonsurgically, study finds

ROSEMONT, Ill., March 2 /PRNewswire-USNewswire/ -- Injuries to the knee's medial cruciate ligament (MCL) may be treated successfully without surgery, according to a literature review published in the March 2009 issue of The Journal of the American Academy of Orthopaedic Surgeons (JAAOS). The key, the review's authors found, is properly diagnosing and understanding the extent of the injury to determine the best course of treatment.

The MCL is the most frequently injured ligament in the knee. It attaches to the femur (thigh bone) and the tibia (shin bone) and runs across the inside of the knee. MCL injuries are usually caused by a direct blow to the knee, very common in contact sports such as football, rugby or soccer.

Injuries to the MCL may be isolated, or they may be part of a more complex injury involving the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL) or meniscus (cartilage between the bones in the knee joint). Knowing whether other structures in the knee are involved is vital to treating these injuries.

"In most cases, MCL injuries can be treated non-operatively, with a combination of rehabilitation and bracing," says Ryan G. Miyamoto, M.D., sports medicine fellow at the Steadman-Hawkins Clinic in Vail, Colorado. "Surgery becomes an option when there are multiple injuries present in the knee. However, the additional injuries are not always identified."

Thorough physical examinations and appropriate imaging are of paramount importance in managing MCL injuries, say the study authors. In addition, they add that high-grade MCL injuries are often associated wi
'/>"/>

SOURCE American Academy of Orthopaedic Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
2. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
3. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
4. First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
5. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
6. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
7. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
8. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
9. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
10. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
11. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...TER, N.Y., Dec. 3 Virtua...er of quantitative imaging for clinical trials, an...ethod for 4D Reconstruction and Visualization" rec...pics, Vice President of Technology and Product Dev...ed that Japan has recognized the uniqueness of Vir...
(Date:12/3/2009)..., ROTTERDAM, The Netherlands, December 3 /PR...ny focused on the discovery and development of hum...y(TM) platform, today,announced the successful sec.... The Company raised an additional EUR 3.0 million...investors, Credit Agricole Private Equity and,VIB ...
(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com...ailable in its catalogue: ,, Cardiac Pacemake...eportlinker.com/p0164335/Cardiac-Pacemakers---A-Wo...constitute a major segment in a rapidly expanding ...ac pacemakers market is characterized by relativel...
Breaking Medicine Technology:VirtualScopics Receives Issuance in Japan of Prominent Patent 2VirtualScopics Receives Issuance in Japan of Prominent Patent 3arGEN-X Concludes EUR 12.5 Million Series A Financing Round 2arGEN-X Concludes EUR 12.5 Million Series A Financing Round 3arGEN-X Concludes EUR 12.5 Million Series A Financing Round 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call 5713 1ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call 5713 2MedPlus Maintains Top Ranking in KLAS Industry Report 5710 1MedPlus Maintains Top Ranking in KLAS Industry Report 5710 2MedPlus Maintains Top Ranking in KLAS Industry Report 5710 3MedPlus Maintains Top Ranking in KLAS Industry Report 5710 4Reportlinker Adds Outsourcing Preclinical Studies to China 5707 1Reportlinker Adds Outsourcing Preclinical Studies to China 5707 2Reportlinker Adds Outsourcing Preclinical Studies to China 5707 3Reportlinker Adds Outsourcing Preclinical Studies to China 5707 4Reportlinker Adds Outsourcing Preclinical Studies to China 5707 5Reportlinker Adds Outsourcing Preclinical Studies to China 5707 6
...r Similar to Seven-Day in, Achieving Red Blood Cel...t in All MDS Patients Tested...Hematology (ASH) Meeting, ATLANTA, Dec. 11 Pharm...nterim data from a Phase 2 clinical trial,evaluati... Vidaza(R),(azacitidine for injection) that demons...
...city With Equivalent Complete Re...erapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) ann...II/III randomized study comparing CPOP-R to CHOP-R...essive non-Hodgkin,s lymphoma,(NHL) showed patient...(grade 3/4) toxicities including severe infection ...
Other Medicine Technology:MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 2MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 3MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 5MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 6Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5
(Date:12/3/2009)...sue of Deutsches rzteblatt International contain...xperience with the novel influenza A virus (H1N1/0...t of the pandemic. Ralf Winzer and his coauthors f...ely evaluated data from a large clinical cohort of...2009; 106[47]: 770-6). Their medical-scientific ar...
(Date:12/3/2009)... 450 Deaths a day is still too many - s...k. , Atlanta, GA, Geneva,...3, 2009 -- The Measles Initiative announced today ...2000 and 2008, from an estimated 733 000 in 2000 t...perts warn of a resurgence in measles deaths if va...
(Date:12/3/2009)... Nutra Pharma will be conducting a webi...squo;s over-the-counter and prescription treatment... Plantation, FL (Vocus) Decem... biotechnology company that is developing treatmen...le Sclerosis (MS), has announced today that it wil...
(Date:12/3/2009)...ANTA ROSA, Calif., Dec. 3 Osseon T...eerable and curvable bone cement delivery needle) ...l) systems for percutaneous vertebral augmentation...alth Canada for marketing and clinical use in Cana... corresponds to FDA approval in the United States,...
(Date:12/3/2009)...AScientists at Boston Biomedical Research Institut...ound that combining two chemicals, one of which is...stroy a variety of protein structures known as amy...brain disorders such as Alzheimer,s, Huntington,s,... in the current issue of Nature Chemical Biology ...
Breaking Medicine News(10 mins):Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 3Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 4Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 3Health News:Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada 2Health News:Green tea chemical combined with another may hold promise for treatment of brain disorders 2
... Dr. Wayne Andersen to discuss weight management...uot; which is helping thousands maintain permanent...le-Dublin, Ohio (PRWEB) April 30, 2009 -- Dr. Wayn...three free seminars in the Westerville-Dublin area...
... G1G Travel Insurance and Student Funding Group ...l safely; Tuition Fee protection programs also add...se, CA (PRWEB) April 30, 2009 -- With a rise in in...udent Funding Group (StuFund) to offer newly creat...
...and, Ore.) A brief intervention program consisti...ne calls boosted by tenfold the number of women c...the findings of a Kaiser Permanente Center for Hea...intervention programs can be effective in increasi...
...illion in Total Revenues for the Quarter , , SAN ... Realty Trust, Inc. (NYSE: BMR ), a real estate ...to the Life Science Industry(R), today announced o...ter were $94.0 million, up 39.5% from $67.4 millio...
... VA,s Office of Research and Development is at th...eatments based on new knowledge about the role of ... to study genomics--the use of patients, individua...ed network of basic research and clinical applicat...
...ining the mechanism of a novel therapy that uses m... showed the treatment to be a promising alternativ...nial magnetic stimulation, or TMS. Study findings...ntrolled clinical study by Ohio State University M...
Other Medicine News:Health News:Physician and Author to Share Clinically Proven System for Permanent Weight Loss and Optimal Health in Westerville and Dublin, Ohio Areas 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 3Health News:Women 10 times more likely to do breast self-exams correctly with intervention, KP study finds 2Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 2Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 3Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 4Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 5Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 6Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 7Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 8Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 9Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 10Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 11Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 12Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 13Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 14Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 15Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 16Health News:BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results 17Health News:Video: Turning Hope Into Reality - Genomics Research at the VA 2Health News:New therapy based on magnetic stimulation shows promise for non-drug treatment for migraine 2
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: